Q2 2026 Holdings
Filed 2026-08-14 | 37 holdings | $1.6B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc.(CGEM) | 230031106 | 230031106 | $177.2M | 9,731,341 | 10.8% |
| Aktis Oncology, Inc.(AKTS) | 01021M104 | 01021M104 | $155.9M | 4,835,872 | 9.5% |
| Liquidia Corporation(LQDA) | 53635D202 | 53635D202 | $110.5M | 1,386,174 | 6.7% |
| Revolution Medicines, Inc.(RVMD) | 76155X100 | 76155X100 | $92.2M | 492,483 | 5.6% |
| Corcept Therapeutics, Inc.(CORT) | 218352102 | 218352102 | $67.0M | 771,028 | 4.1% |
| Edgewise Therapeutics Inc(EWTX) | 28036F105 | 28036F105 | $65.9M | 1,620,780 | 4.0% |
| Travere Therapeutics Inc(TVTX) | 89422G107 | 89422G107 | $63.8M | 1,122,731 | 3.9% |
| DBV Technologies S A(DBVT) | 23306J309 | 23306J309 | $60.1M | 3,666,284 | 3.7% |
| Trevi Therapeutics Inc(TRVI) | 89532M101 | 89532M101 | $57.3M | 3,073,577 | 3.5% |
| Alumis Inc(ALMS) | 022307102 | 022307102 | $56.8M | 2,019,020 | 3.5% |
| Uniqure NV(QURE) | N90064101 | N90064101 | $56.5M | 1,225,855 | 3.4% |
| Ultragenyx Pharmaceuticals, Inc.(RARE) | 90400D108 | 90400D108 | $47.4M | 1,418,215 | 2.9% |
| Relay Therapeutics Inc.(RLAY) | 75943R102 | 75943R102 | $45.2M | 2,415,672 | 2.8% |
| Abivax SA(ABVX) | 00370M103 | 00370M103 | $44.8M | 336,347 | 2.7% |
| Dyne Therapeutics, Inc.(DYN) | 26818M108 | 26818M108 | $42.7M | 1,922,093 | 2.6% |
| Dianthus Therapeutics Inc(DNTH) | 252828108 | 252828108 | $40.9M | 420,002 | 2.5% |
| Bioage Labs Inc(BIOA) | 09077V100 | 09077V100 | $40.9M | 1,667,661 | 2.5% |
| Urogen Pharma Ltd(URGN) | M96088105 | M96088105 | $34.3M | 933,415 | 2.1% |
| MoonLake Immunotherapeutics(MLTX) | 61559X104 | 61559X104 | $31.3M | 1,606,967 | 1.9% |
| Palvella Therapeutics Inc(PVLA) | 697947109 | 697947109 | $31.2M | 204,027 | 1.9% |
| Taysha Gene Therapies, Inc.(TSHA) | 877619106 | 877619106 | $30.6M | 4,500,000 | 1.9% |
| Syndax Pharmaceuticals Inc(SNDX) | 87164F105 | 87164F105 | $29.2M | 1,333,523 | 1.8% |
| Monte Rosa Therapeutics Inc(GLUE) | 61225M102 | 61225M102 | $28.1M | 1,161,081 | 1.7% |
| Zura Bio Ltd.(ZURA) | G9TY5A101 | G9TY5A101 | $26.4M | 4,472,843 | 1.6% |
| Natera Inc(NTRA) | 632307104 | 632307104 | $25.1M | 92,638 | 1.5% |
| Stoke Therapeutics Inc(STOK) | 86150R107 | 86150R107 | $23.7M | 723,314 | 1.4% |
| Adlai Nortye Ltd(ANL) | 00704R109 | 00704R109 | $22.3M | 1,936,291 | 1.4% |
| Belite Bio Inc(BLTE) | 07782B104 | 07782B104 | $21.1M | 137,208 | 1.3% |
| Forte Biosciences, Inc.(FBRX) | 34962G208 | 34962G208 | $21.0M | 987,448 | 1.3% |
| Oric Pharmaceuticals Inc(ORIC) | 68622P109 | 68622P109 | $20.4M | 1,882,162 | 1.2% |
| Tarsus Pharmaceuticals Inc(TARS) | 87650L103 | 87650L103 | $20.3M | 322,007 | 1.2% |
| Annexon Inc(ANNX) | 03589W102 | 03589W102 | $20.2M | 3,544,354 | 1.2% |
| Bright Minds Biosciences Inc(DRUG) | 10919W405 | 10919W405 | $14.2M | 202,114 | 0.9% |
| Entrada Therapeutics, Inc.(TRDA) | 29384C108 | 29384C108 | $9.2M | 1,253,053 | 0.6% |
| Aclaris Therapeutics Inc(ACRS) | 00461U105 | 00461U105 | $5.5M | 1,042,467 | 0.3% |
| Context Therapeutics Inc(CNTX) | 21077P108 | 21077P108 | $719.5K | 1,299,046 | 0.0% |
| Werewolf Therapeutics, Inc.(HOWL) | 95075A107 | 95075A107 | $28.9K | 80,142 | 0.0% |